Organogenesis Holdings (ORGO) EBITDA (2016 - 2026)

Organogenesis Holdings' EBITDA history runs 11 years deep, the most recent figure standing at -$68.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 157.57% year-over-year to -$68.9 million; the TTM figure through Mar 2026 stood at -$32.3 million (down 33.52% YoY), while the FY2025 annual figure was $9.9 million, up 868.82% from the prior year.
• EBITDA was -$68.9 million for Q1 2026 at Organogenesis Holdings, down from $28.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $28.5 million in Q4 2025 to a low of -$68.9 million in Q1 2026.
• Historically, EBITDA has averaged -$1.5 million across 5 years, with a median of $1.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA sank 3025.78% in 2023, then jumped 905.28% in 2024.
• A 5-year view of EBITDA shows it stood at $8.7 million in 2022, then slumped by 114.56% to -$1.3 million in 2023, then surged by 905.28% to $10.2 million in 2024, then jumped by 178.49% to $28.5 million in 2025, then slumped by 342.07% to -$68.9 million in 2026.
• The last three EBITDA figures came in at -$68.9 million (Q1 2026), $28.5 million (Q4 2025), and $20.7 million (Q3 2025), per Business Quant data.